Action of antiproteases on the inflammatory response in acute pancreatitis

Journal of the Pancreas

Volumn 8, Issue 4, 2007, Pages 488-494

  Chen, Chun Chia ^a   Wang, Sun Sang ^a   Lee, Fa Yauh ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Aprotinin; Cytokines; Gabexate; Nafamostat; Pancreatitis; Protease inhibitors; Urinastatin

Indexed keywords

4 (2 AMINOETHYL)BENZENESULFONYL FLUORIDE; AMYLASE; APROTININ; CARBOXYLASE; CERULETIDE; CHYMOTRYPSIN; COMPLEMENT COMPONENT C1; CYTOKINE; GABEXATE MESILATE; INTERLEUKIN 1BETA; KALLIKREIN; LEUKOCYTE ELASTASE; NAFAMSTAT; PHOSPHOLIPASE A2; PLASMIN; PROTEINASE ACTIVATED RECEPTOR 2; PROTEINASE INHIBITOR; THROMBIN; TRIACYLGLYCEROL LIPASE; TRYPSIN; TRYPSIN INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; ULINASTATIN;

ACUTE PANCREATITIS; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; CONTINUOUS INFUSION; DISEASE SEVERITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MORTALITY; MULTIPLE ORGAN FAILURE; NONHUMAN; PATHOGENESIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

HUMANS; PANCREATITIS; PROTEASE INHIBITORS;

EID: 34547929954     PISSN: None     EISSN: 15908577     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (59)

1. Banks PA. Acute pancreatitis: medical and surgical management. Am J Gastroenterol 1994; 89:S78-85.
2. Granger J, Remick D. Acute pancreatitis: models, markers, and mediators. Shock 2005; 24:45-51.
3. Saluja AK, Steer ML. Pathophysiology of pancreatitis. Role of cytokines and other mediators of inflammation. Digestion 1999; 60:27-33.
4. Ohnishi H, Kosuzume H, Ashida Y, Kato K, Honjo I. Effects of urinary trypsin inhibitor on pancreatic enzymes and experimental acute pancreatitis. Dig Dis Sci 1984; 29:26-32.
5. Wisner JR Jr, Renner IG, Grendell JH, Niederau C, Ferrell LD. Gabexate mesilate (FOY) protects against ceruletide-induced acute pancreatitis in the rat. Pancreas 1987; 2:181-6.
6. Suzuki M, Isaji S, Stanten R, Frey CF, Ruebner B. Effect of protease inhibitor FUT-175 on acute hemorrhagic pancreatitis in mice. Int J Pancreatol 1992; 11:59-65.
7. Dabrowski A, Gabryelewicz A. The effect of nafamostat mesilate (FUT-175) and gabexate mesilate (FOY) on multiorgan oxidant-antioxidant balance in acute experimental pancreatitis. J Physiol Pharmacol 1994; 45:455-65.
8. Chen HM, Shyr MH, Chen MF. Gabexate mesilate improves pancreatic microcirculation and reduces lung edema in a rat model of acute pancreatitis. J Formos Med Assoc 1997; 96:704-9.
9. Hartwig W, Werner J, Jimenez RE, Z'graggen K, Weimann J, Lewandrowski KB, et al. Trypsin and activation of circulating trypsinogen contribute to pancreatitis-associated lung injury. Am J Physiol 1999; 277:G1008-16.
10. Chen CC, Wang SS, Tsay SH, Lee FY, Lu RH, Chang FY, Lee SD. Effects of gabexate mesilate on serum inflammatory cytokines in rats with acute necrotizing pancreatitis. Cytokine 2006; 33:95-9.
11. Goebell H. Multicenter double-blind study of gabexate mesilate (Foy) given intravenously in low dose in acute pancreatitis. Digestion 1988; 40:83.
12. Pederzoli P, Cavallini G, Falconi M, Bassi C. Gabexate mesilate vs aprotinin in human acute pancreatitis (GA.ME.P.A.). A prospective, randomized, double-blind multicenter study. Int J Pancreatol 1993; 14:117-24.
13. Buchler M, Malfertheiner P, Uhl W, Scholmerich J, Stockmann F, Adler G, et al. Gabexate mesilate in human acute pancreatitis. German Pancreatitis Study Group. Gastroenterology 1993; 104:1165-70.
14. Yang CY, Chang-Chien CS, Liaw YF. Controlled trial of protease inhibitor gabexate mesilate (Foy) in the treatment of acute pancreatitis. Pancreas 1987; 6:698-700.
15. Valderrama R, Perez-Mateo M, Navarro S, Vazquez N, Sanjose L, Adrian MJ, Estruch J. Multicenter double-blind trial of gabexate mesilate (FOY) in unselected patients with acute pancreatitis. Digestion 1992; 51:65-70.
16. Cavallini G, Tittobello A, Frulloni L, Masci E, Mariana A, Di Francesco V. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy. Italian Group. N Engl J Med 1996; 335:919-23.
17. Andriulli A, Solmi L, Loperfido S, Leo P, Festa V, Belmonte A, et al. Prophylaxis of ERCP-related pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesylate. Clin Gastroenterol Hepatol 2004; 2:713-8.
18. Andriulli A, Leandro G, Federici T, Ippolito A, Forlano, R, Iacobellis A, Annese V. Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis. Gastrointest Endosc 2007; 65:624-32.
19. Gross V, Leser HG, Heinisch A, Scholmerich J. Inflammatory mediators and cytokines-new aspects of the pathophysiology and assessment of severity of acute pancreatitis? Hepatogastroenterology 1993; 40:522-30.
20. Hirota M, Ohmuraya M, Baba H. The role of trypsin, trypsin inhibitor, and trypsin receptor in the onset and aggravation of pancreatitis. J Gastroenterol 2006; 41:832-6.
21. Makhija R, Kingsnorth AN. Cytokine storm in acute pancreatitis. J Hepatobiliary Pancreat Surg 2002; 9:401-10.
22. Rinderknecht H. Fatal pancreatitis, a consequence of excessive leukocyte stimulation? Int J Pancreatol 1988; 3:105-12.
23. Leser HG, Gross V, Scheibenbogen C, Heinisch A, Salm R, Lausen M, et al. Elevation of serum interleukin-6 concentration precedes acute phase response and reflects severity in acute pancreatitis. Gastroenterology 1991; 101:782-5.
24. Chen CC, Wang SS, Lee FY, Chang FY, Lee SD. Proinflammatory cytokines in early assessment of the prognosis of acute pancreatitis. Am J Gastroenterol 1999; 94:213-8.
25. Bhatia M, Brady M, Shokuhi S, Christmas S, Neoptolemos JP, Slavin J. Inflammatory mediators in acute pancreatitis. J Pathol 2000; 190:117-25.
26. Chen CC, Wang SS, Lu RH, Chang FY, Lee SD. Serum interleukin 10 and interleukin 11 in patients with acute pancreatitis. Gut 1999; 45:895-9.
27. Mayer J, Rau B, Gansauge F, Beger HG. Inflammatory mediators in human acute pancreatitis: clinical and pathophysiological implications. Gut 2000; 47:546-52.
28. Chen CC, Wang SS, Lu RH, Lu CC, Chang FY, Lee SD. Early changes of serum proinflammatory and anti-inflammatory cytokines after endoscopic retrograde cholangiopancreatography. Pancreas 2003; 26:375-80.
29. Rettally CA, Skarda S, Garza MA, Schenker S. The usefulness of laboratory tests in the early assessment of severity of acute pancreatitis. Crit Rev Clin Lab Sci 2003; 40:117-49.
30. Chen CC. Serum markers in the early assessment of severity of acute pancreatitis: Which is the most useful? J Chin Med Assoc 2004; 67:439-41.
31. Haberland G, McConn R. A rationale for the therapeutic action of aprotinin. Fed Proc 1979; 38:2760-7.
32. Lasson A, Ohlsson K. Protease inhibitors in acute human pancreatitis. Correlation between biochemical changes and clinical course. Scand J Gastroenterol 1984; 19: 779-86.
33. Trapnell JE, Rigby CC, Talbot CH, Duncan EH. A controlled trial of Trasylol in the treatment of acute pancreatitis. Br J Surg 1974; 61:177-82.
34. Imrie CW, Benjamin IS, Ferguson JC, McKay AJ, Mackenzie I, O'Neill J, et al. A single-centre double-blind trial of Trasylol therapy in primary acute pancreatitis. Br J Surg 1978; 65:337-41.
35. Morbidity of acute pancreatitis: the effect of aprotinin and glucagon. Gut 1980; 21:334-9.
36. Watanabe S. Acute pancreatitis: overview of medical aspects. Pancreas 1998; 16:307-11.
37. Ino Y, Suzuki K, Sato T, Iwaki M. Comparative studies of nafamostat mesilate and various serine protease inhibitors in vitro. Nippon Yakurigaku Zasshi 1986; 88:449-55.
38. Iwaki M, Ino Y, Motoyoshi A, Ozeki M, Sato T, Kurumi M, Aoyama T. Pharmacological studies of FUT-175, nafamostat mesilate. V. Effects on the pancreatic enzymes and experimental acute pancreatitis in rats. Jpn J Pharmacol 1986; 41:155-62.
39. Waxler B, Rabito SF. Aprotinin: a serine protease inhibitor with therapeutic actions: its interaction with ACE inhibitors. Curr Pharm Des 2003; 9:777-87.
40. Day JR, Taylor KM, Lidington EA, Mason JC, Haskard DO, Randi AM, Landis RC. Aprotinin inhibits proinflammatory activation of endothelial cells by thrombin through the protease-activated receptor 1. J Thorac Cardiovasc Surg 2006; 131:21-7.
41. Hill GE, Pohorecki R, Alonso A, Rennard SI, Robbins RA. Aprotinin reduces interleukin-8 production and lung neutrophil accumulation after cardiopulmonary bypass. Anesth Analg 1996; 83:696-700.
42. Hill GE, Alonso A, Spurzem JR, Stammers AH, Robbins RA. Aprotinin and methylprednisolone equally blunt cardiopulmonary bypass-induced inflammation in humans. J Thorac Cardiovasc Surg 1995; 110:1658-62.
43. Siebeck M, Fink E, Weipert J, Jochum M, Fritz H, Spannagl M, et al. Inhibition of plasma kallikrein with aprotinin in porcine endotoxin shock. J Trauma 1993; 34:193-8.
44. Yuksel M, Okajima K, Uchiba M, Okabe H. Gabexate mesilate, a synthetic protease inhibitor, inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappaB and activator protein-1 in human monocytes. J Pharmacol Exp Ther 2003; 305:298-305.
45. Luh SP, Tsai CC, Shau WY, Chen JS, Kuo SH, Lin-Shiau SY, Lee YC. Effects of gabexate mesilate (FOY) on ischemia-reperfusion-induced acute lung injury in dogs. J Surg Res 1999; 87:152-63.
46. Ono S, Aosasa S, Mochizuki H. Effects of a protease inhibitor on reduction of surgical stress in esophagectomy. Am J Surg 1999; 177:78-82.
47. Sugita H, Ishiko T, Ikei S, Hirota M, Ogawa M. FUT-175 inhibits the production of IL-6 and IL-8 in human monocytes. Res Commun Mol Pathol Pharmacol 1999; 103:57-64.
48. Miyaso H, Morimoto Y, Ozaki M, Haga S, Shinoura S, Choda Y, et al. Protective effects of nafamostat mesilate on liver injury induced by lipopolysaccharide in rats: possible involvement of CD14 and TLR-4 downregulation on Kupffer cells. Dig Dis Sci 2006; 51:2007-12.
49. Chen CL, Wang SD, Zeng ZY, Lin KJ, Kao ST, Tani T, et al. Serine protease inhibitors nafamostat mesilate and gabexate mesilate attenuate allergen-induced airway inflammation and eosinophilia in a murine model of asthma. J Allergy Clin Immunol 2006; 118:105-12.
50. Endo S, Inada K, Yamashita H, Takakuwa T, Nakae H, Yamada Y, et al. The inhibitory actions of protease inhibitors on the production of polymorphonuclear leukocyte elastase and interleukin 8. Res Commun Chem Pathol Pharmacol 1993; 82:27-34.
51. Ambiru S, Miyazaki M, Sasada K, Ito H, Kimura F, Nakagawa K, et al. Effects of perioperative protease inhibitor on inflammatory cytokines and acute-phase proteins in patients with hepatic resection. Dig Surg 2000; 17:337-43.
52. Nakanishi K, Takeda S, Sakamoto A, Kitamura A. Effects of ulinastatin treatment on the cardiopulmonary bypass-induced hemodynamic instability and pulmonary dysfunction. Crit Care Med 2006; 34:1351-7.
53. Sun JL, Zhang XQ, Yu ZG, Ma R, Dai Y, Fan ZY, Sun JZ. Effects of ulinastatin on postoperative systemic inflammatory response of recipients of rat small bowel transplantation. Transplant Proc 2006; 38:1803-4.
54. Pezzilli R, Barakat B, Morselli-Labate AM. Evaluation of the immunomodulatory effect of gabexate mesilate in patients with severe acute pancreatitis. Curr Ther Res 1998; 59:710-6.
55. Mikami Y, Takeda K, Matsuda K, Qiu-Feng H, Fukuyama S, Egawa S, et al. Rat experimental model of continuous regional arterial infusion of protease inhibitor and its effects on severe acute pancreatitis. Pancreas 2005; 30:248-53.
56. Maeda K, Hirota M, Kimura Y, Ichihara A, Ohmuraya M, Sugita H, Ogawa M. Proinflammatory role of trypsin and protease-activated receptor-2 in a rat model of acute pancreatitis. Pancreas 2005; 31:54-62.
57. Ma T, Kang C, Shao H, Qi Q, Hu W. Protective effects of ulinastatin on proliferation and cytokine release of splenocytes from rats with severe acute pancreatitis. Eur Surg Res 2006; 38:445-50.
58. Shi C, Zhao X, Wang X, Zhao L, Andersson R. Potential effects of PKC or protease inhibitors on acute pancreatitis-induced tissue injury in rats. Vascul Pharmacol 2007; 46:406-11.
59. Kitagawa M, Hayakawa T. Antiproteases in the treatment of acute pancreatitis. JOP. J Pancreas (Online) 2007; 8:518-525.